Acrivon Therapeutics is a biotech company specialized in accelerated drug development using a unique, predictive biomarker approach, with the purpose to significantly improve their commercial value and time on market. Acrivon ensures success in the right patients by increasing efficacy and reducing risk of failure. The company has unique and patented technology platforms to reduce toxicity through chemical design, and to accelerate in-licensed drugs to the clinic by matching patients using predictive phosphoproteomics (AP3) and artificial intelligence. Acrivon brings the drug candidate to clinical proof-of-concept and is currently focusing on oncology and inflammatory diseases.